First mRNA vaccine for deadly nipah virus shows promise in early trial
NCT ID NCT05398796
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 37 times
Summary
This early-stage trial tested an experimental mRNA vaccine (mRNA-1215) for Nipah virus, a serious disease spread from animals and people. Forty healthy adults received two shots, one month apart, and were monitored for safety and immune response over about a year. The vaccine cannot cause Nipah infection and aims to prevent this often-fatal illness.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NIPAH VIRUS INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.